Search Result

Basic Information

Classification Information

Regulatory Mechanism		Biological Function		Clinical Application
TF		Immune		Survival
Enhancer		Apoptosis	apoptosis	Drug	Cisplatin
Variant		Cell Growth		Circulating
MiRNA		EMT		Metastasis
Methylation		Coding Ability		Recurrence

Cancer&Entry Information

Cancer Name	ovarian cancer
ICD-0-3	C56.9
Methods	qRT-PCR , Luciferase reporter assay , Western blot etc.
Sample	epithelial ovarian cancer tissues, normal ovarian tissues ,normal human ovarian surface epithelial cells (HOSEPiCs) , human ovarian cancer cells (cisplatin-sensitive strain SKOV3 and cisplatin-resistant strain SKOV3/DDP)
Expression Pattern	up-regulated
Function Description	Ovarian cancer tissues and cisplatin-resistant cells had increased ANRIL expression and decreased let-7a expression, and those patients with higher clinical stage and pathological grade showed higher ANRIL and lower let-7a. Dual-luciferase reporter-gene assay confirmed the targeting relationship between ANRIL and let-7a, and between let-7a and HMGA2. The cell viability and cisplatin IC50 were decreased in ANRIL siRNA group exposed to different concentrations of cisplatin, with enhanced apoptosis, as well as elevated let-7a and declined HMGA2.Meanwhile, ANRIL down-regulation enhanced the inhibitory effect of cisplatin on tumor growth of nude mice and reduced tumor weight.Silencing ANRIL expression reduced HMGA2 expression to promote the apoptosis and improve cisplatin-sensitivity of ovarian cancer cells via up-regulating let-7a expression.
Pubmed ID	31189742
Year	2019
Title	LncRNA ANRIL Affects the Sensitivity of Ovarian Cancer to Cisplatin via Regulation of let-7a/HMGA2 Axis

External Links